scholarly journals Ultrasound of the chest and mediastinum in children, interventions and artefacts. WFUMB review paper (part 3)

2021 ◽  
Author(s):  
Cheng Fang ◽  
Joanna Jaworska ◽  
Natalia Buda ◽  
Ioana Mihaiela Ciuca ◽  
Yi Dong ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Ionizing Radiation ◽  
Chest Wall ◽  
Temporal Resolution ◽  
Diagnostic Tool ◽  
Review Paper ◽  
First Line ◽  
The Third ◽  
Technical Requirements ◽  
Paediatric Patients

Ultrasound (US) is an ideal diagnostic tool for paediatric patients owning to its high spatial and temporal resolution, realtime imaging, and lack of ionizing radiation and bedside availability. The lack of superficial adipose tissue and favourable acoustic windows in children makes US the first line of investigation for evaluation of pleural and chest wall abnormalities.In the first part of the topic the technical requirements were explained and the use of ultrasound in the lung and pleura in paediatric patients were discussed. In the second part lung parenchymal diseases with their subpleural consolidations are reflected. In the third part, the use of ultrasound for chest wall, mediastinum, diaphragmatic diseases, trachea, interventions and artifacts in paediatric patients are summarized.

scholarly journals Ultrasound of the pleura in children, WFUMB review paper

2021 ◽  
Author(s):  
Joanna Jaworska ◽  
Natalia Buda ◽  
Ioana Mihaiela Ciuca ◽  
Yi Dong ◽  
Cheng Fang ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Review Paper ◽  
Lung Ultrasound ◽  
Point Of Care ◽  
Lung Parenchyma ◽  
World Federation ◽  
First Line ◽  
Technical Requirements ◽  
Contrast Enhanced ◽  
Valuable Point

Ultrasound (US) is an ideal diagnostic tool for paediatric patients owning to its high spatial and temporal resolution, real-time imaging, and lack of ionizing radiation and bedside availability. The lack of superficial adipose tissue and favorable acoustic windows in children makes US the first line of investigation for the evaluation of pleural and chest wall abnormali-ties. Lung parenchyma was previously thought to be inaccessible to ultrasound due to the presence of the air and bony thorax. The change in attitude and growing awareness of the diagnostic possibilities has led to lung ultrasound (LUS) being accepted as a valuable point of care method. In addition, the application of LUS has widened with improvements in technology such as higher resolution transducers, harmonic imaging and contrast-enhanced ultrasound. In the current World Federation of Societies for Ultrasound in Medicine and Biology (WFUMB) paper series the topic will be introduced, the technical requirements explained and the use of ultrasound in the lung and pleura in pediatric patients are discussed.

scholarly journals Retrograde Approach for Intra-arterial Chemotherapy Delivery in Retinoblastoma

2021 ◽  
Author(s):  
Giancarlo Saal-Zapata ◽  
Walter Durand ◽  
Alfredo Ramos ◽  
Raúl Cordero ◽  
Rodolfo Rodríguez
Keyword(s):  
Internal Carotid ◽  
Middle Meningeal Artery ◽  
Posterior Circulation ◽  
Alternative Form ◽  
Chemotherapeutic Drugs ◽  
Retrograde Approach ◽  
First Line ◽  
The Third ◽  
Cure Rates ◽  
Meningeal Artery

AbstractIntra-arterial chemotherapy (IAC) is currently, the first-line treatment for retinoblastomas with successful cure rates. In difficult access or unsuccessful catheterization of the ophthalmic artery (OA), the middle meningeal artery is a second alternative followed by the Japanese technique using balloon. Nevertheless, when a well-developed posterior communicating artery is present, a retrograde approach to the OA through this vessel can be performed to deliver the chemotherapeutic drugs.We present a case of an unsuccessful catheterization of the OA through the internal carotid artery due to a challenging configuration of the OA/carotid siphon angle and describe an alternative form of navigation and catheterization through the posterior circulation.To our knowledge, this is the third report of a successful retrograde catheterization of the OA for IAC and constitutes an alternative route to deliver chemotherapy.

scholarly journals AB0751 SAFETY AND PERSISTENCE OF USTEKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS IN BIOBADASER

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1672.2-1672
Author(s):  
N. Busquets-Pérez ◽  
C. Sánchez-Piedra ◽  
P. Vela-Casasempere ◽  
M. Freire-Gonzalez ◽  
C. Bohórquez ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Adverse Events ◽  
First Year ◽  
Line Treatment ◽  
Minimal Disease Activity ◽  
First Line ◽  
The Third ◽  
Minimal Disease ◽  
Second Year ◽  
Third Line

Background:Ustekinumab has been efficacy and safety for psoriatic artritis in clinical trials.Objectives:To assess effectiveness, by means of drug persistence analisys, and safety of ustekinumab in patients with psoriastic arthritis in Biobadaser.Methods:BIOBADASER is the Spanish registry of biological drugs of the Spanish Society of Rheumatology and the Spanish Medicines Agency. We identified patients aged 18 years or more with psoriatic arthritis on Ustekinumab. A descriptive analysis was performed.The persistence of ustekinumab therapy was calculated with a Kaplan-Meier curve and was compared with the persistence of anti-TNF, according to line treatment. Log Rank test was used to establish a comparison. Adverse events occurring with ustekinumab are described according to year treatment.Results:One hundred and twelve patients were on ustekinumab. Most of them were on their second or third line treatment: 53.57% more than one biological therapy (BT), 19.64% second BT, 26.79% were naïve for BT. Most of them were on 45 mg dose: 88.24%. Median duration of disease at Ustekinumab initiation was 10.1 SD 7.2 years; 69.23% had peripheral arthritis; 45.24% had obesity and 39.29% were overweight; 40,6% were on prednisone and 59.82% on DMARD. The cause of discontinuation of treatment was mainly inefficacy (82.61%) and less common an adverse event (6.52%). The probability of persistence of treatment with ustekinumab was 0.83 (95% CI 0.63-0.92) at year 1, 0.79 (0.58-0.90) at year 2 and 0.79 (0.58-0.9) at year 3 when ustekinumab was prescribed as the first line treatment. The persistence decrease when ustekinumab was prescribe as a second and third treatment: being 0.53 (0.27-0.73) the first year, 0.46 (0.22-0.67) the second year and 0.46 (0.22-0.67) as a second line treatment and 0.58 (0.44-0.70) the first year, 0.33 (0.17-0.50) the second year and 0.33 (0.17-0.50) the third year as a third line treatment.The persistence was similar to anti-TNF treatment, according to line treatment. Adverse events were mainly mild (97.83%) and occurred the first year of treatment. Most of the adverse events were classified as “infections and infestations” (36.96%).Conclusion:The persistence of ustekinumab was high, being 83% at the end of the first year on treatment and 79% the second and the third year of treatment. The persistence of ustekinumab was higher when if it was the first line treatment compared as if it was used as the second o third BT option. The persistence of Ustekinumab is similar to the persistence of anti-TNF treatments in all the analyzed treatment lines (no statistically differences were found). Adverse events occurred mainly during the first year treatment. They were mainly mild adverse events and the frequency decreased within the second and third year of treatment.References:[1]Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.Almirall M, Rodriguez J, Mateo L, Carrascosa JM, Notario J, Gallardo F. Clin Rheumatol. 2017 Feb;36(2):439-443;[2]Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.Napolitano M, Costa L, Caso F, Megna M, Scarpa R, Balato N, Ayala F, Balato A. J Clin Rheumatol. 2018 Oct;24(7):381-384;[3]Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.Queiro R, Brandy A, Rosado MC, Lorenzo A, Coto P, Carriles C, Alperi M, Ballina J. Actas Dermosifiliogr. 2018 Jun 28;[4]An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.Salgüero Fernández I, Gil MH, Sanz MS, Gullón GR;Disclosure of Interests:None declared

FEATURES OF PLEURAL CAVITY DRAINAGE IN PATIENTS WITH ACUTE NONSPECIFIC PLEURAL EMPYEMA

2020 ◽  
pp. 39-42
Author(s):  
D. V. Minukhin ◽  
O. I. Tsyvenko ◽  
A. Yu. Korolevska ◽  
L. G. Tarasenko ◽  
D. Yu. Melnyk ◽  
...  
Keyword(s):  
Chest Wall ◽  
Pleural Cavity ◽  
Pleural Empyema ◽  
Pleural Drainage ◽  
Main Method ◽  
Second Stage ◽  
The Third ◽  
Third Stage ◽  
Minor Surgery ◽  
Surgical Manipulation

Most authors considered pleural cavity drainage to be the main method of treatment of acute pleural empyema using minor surgery. Despite the simplicity of drainage of the pleural cavity, the number of complications after this surgical manipulation, according to the reports of some authors, varies from 3 to 8 %. The complications of pleural drainage in the patients with acute nonspecific pleural empyema have been studied and the technique of pleural drainage "blindly" has been introduced, which allows drainage to be located along the chest wall. At the first stage of the four−stage study, the complications of pleural drainage in 38 patients with acute nonspecific pleural empyema were analyzed, at the second stage a device for drainage of the pleural cavity "blindly" was developed to place drainage in parallel to the chest wall, at the third stage patients were tested; on IV −− drainage of the pleural cavity of 34 patients was performed according to the proposed method. The reason for the development of drainage complications in the pleural cavity of patients with acute pleural empyema was the inadequate location of drainage in the pleural cavity, drainage of the pleural cavity was carried out in general hospitals without the use of thoracoscopic equipment. Curved thoracoport with trocar for a blind drainage of the pleural cavity "blindly" was developed and introduced into clinical practice. This technique eliminates the involuntary location of the drainage in the pleural cavity, installing it along the chest wall, and is safe. Complications associated with drainage of the pleural cavity according to the developed method using a curved thoracoport with a trocar, inadequate location of drainage, were not observed in patients. Key words: acute pleural empyema, pleural cavity drainage, curved trocar.

scholarly journals DESCRIPTION OF A NEW ARCTIA FROM COLORADO

1871 ◽  
Vol 3 (9) ◽  
pp. 167-167 ◽  
Author(s):  
CHAS. R. DODGE
Keyword(s):  
Costal Margin ◽  
Broad Line ◽  
First Line ◽  
Posterior Angle ◽  
Transverse Band ◽  
The Third ◽  
Straight Lines

Anterior wings rich chocolate - brown with creamy white stripes or markings. Costal margin lighter brown. A broad line running from the base of the median vein nearly to the posterior angle, where it becomes slightly forked; from this proceeds a slightly curved narrower branch, from the centre of the wing nearly to the costal edge, and one-third the distance from the apex ; a zigzag mark composed of three straight lines, the first being the broadest, and the third one-half the length of the others, proceeds from the outer angle, where it joins the first line, and terminates under the costal edge; the whole forming a distinct W crossed at the top by the transverse band. Inner edge faintly marked with creamy white.

scholarly journals Adenolipoma of the Skin: A Report of 11 Cases

2018 ◽  
Vol 10 (1) ◽  
pp. 76-81 ◽  
Author(s):  
Rawan  Amir ◽  
Salwa  Sheikh
Keyword(s):  
Adipose Tissue ◽  
Mast Cells ◽  
Benign Lesion ◽  
Case Series ◽  
Lower Leg ◽  
Apocrine Glands ◽  
Mature Adipose Tissue ◽  
The Third ◽  
Male Ratio ◽  
Eccrine Glands

Introduction: Adenolipoma is a relatively recently described lesion representing a rare variant of lipoma in which eccrine glands and ducts are found interspersed amongst mature adipose tissue. This benign lesion was first described by Hitchcock et al. in 1993 [J Am Acad Dermatol 1993; 29: 82–85]. The next case series was written by Ait-Ourhrouil and Grosshans [Ann Dermatol Venerol 1997; 124: 845–848] in which they deemed adenolipoma a misnomer based on the pathophysiology of the lesion and suggested the name peri-sudoral lipoma instead. According to our knowledge, this case series would be the third in the literature to report cases of adenolipoma in an attempt to increase awareness of this entity. Methods: We performed a retrospective review of adenolipoma cases from 2004 to 2014 at our institute. Results and Conclusions: Upon review of all adenolipomas diagnosed at our institute between 2004 and 2014, 11 cases in total were identified. Histologically, these lesions consisted of an admixture of adult-like adipose tissue and scattered eccrine glands and ducts. 4 cases also showed areas of myxoid changes; 2 showed scattered mast cells amongst the adipose tissue, and only 1 showed the presence of apocrine glands in addition to the eccrine glands and ducts. The female to male ratio was 6: 5. The typical age ranged from 41 to 53 years. Adenolipomas were seen arising from various locations including the thighs, gluteal region, lower leg, shoulder, chest, and trunk. The majority of cases were not fully encapsulated and the size varied from 0.7 to 5.8 cm.

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

2001 ◽  
Vol 19 (3) ◽  
pp. 881-894 ◽  
Author(s):  
Paul E. Goss ◽  
Kathrin Strasser
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitors ◽  
Clinical Status ◽  
Phase Iii ◽  
Type I ◽  
Third Generation ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
The Third

PURPOSE: The purpose of this article is to provide an overview of the current clinical status and possible future applications of aromatase inhibitors in breast cancer. METHODS: A review of the literature on the third-generation aromatase inhibitors was conducted. Some data that have been presented but not published are included. In addition, the designs of ongoing trials with aromatase inhibitors are outlined and the implications of possible results discussed. RESULTS: All of the third-generation oral aromatase inhibitors—letrozole, anastrozole, and vorozole (nonsteroidal, type II) and exemestane (steroidal, type I)—have now been tested in phase III trials as second-line treatment of postmenopausal hormone-dependent breast cancer. They have shown clear superiority compared with the conventional therapies and are therefore considered established second-line hormonal agents. Currently, they are being tested as first-line therapy in the metastatic, adjuvant, and neoadjuvant settings. Preliminary results suggest that the inhibitors might displace tamoxifen as first-line treatment, but further studies are needed to determine this. CONCLUSION: The role of aromatase inhibitors in premenopausal breast cancer and in combination with chemotherapy and other anticancer treatments are areas of future exploration. The ongoing adjuvant trials will provide important data on the long-term safety of aromatase inhibitors, which will help to determine their suitability for use as chemopreventives in healthy women at risk of developing breast cancer.

scholarly journals Open removal as a first-line treatment of magnetic intravesical foreign bodies

2013 ◽  
Vol 7 (1-2) ◽  
pp. 25 ◽  
Author(s):  
Max A. Levine ◽  
Howard Evans
Keyword(s):  
Urinary Bladder ◽  
Minimally Invasive ◽  
Foreign Bodies ◽  
Magnetic Beads ◽  
Minimally Invasive Techniques ◽  
Line Treatment ◽  
First Line ◽  
The Third ◽  
Invasive Techniques ◽  
First Line Treatment

Intravesical foreign bodies are an uncommon, but significant, cause of urologic consultation. We present 3 patients who all inserted magnetic beads per urethra into the urinary bladder, which subsequently became retained. Endoscopic attempts were unsuccessfully tried in the first 2 cases, necessitating open cystotomy to remove the beads. The third went straight to open removal. Given the failure of minimally invasive techniques, we believe that open removal should be the first-line treatment for these types of foreign bodies.

Book Vi Of Ennius′ Annals

1987 ◽  
Vol 37 (2) ◽  
pp. 512-514 ◽  
Author(s):  
O. Skutsch
Keyword(s):  
First Line ◽  
General Sense ◽  
The Third ◽  
Second Punic War ◽  
Fall Of Rome

The contents of the sixth book of Ennius' Annals have recently become a matter of dispute. Ever since Columna's edition (1585) it had been assumed that the book was entirely given over to the story of the war against king Pyrrhus (followed perhaps by mention of some events of the next few years; so my commentary, Oxford, 1985, p. 329). That view was based on the anecdote told by Quintilian 6.3.6, that Cicero, asked to say something de Sexto Annali, a witness in a law case, replied: ‘Quis potis ingentis oras euoluere belli’. It seems as good as certain that this was the first line of Book VI, and belli was taken by all as referring to the Pyrrhus war. According to Dr T. Cornell, however, ‘unrolling the mighty scroll of war’ means that the poet is now going to describe warfare on the grand scale, thus setting the sequence of the third Samnite War, the Pyrrhus War, and (the first and) the second Punic War against the minor wars described in the first five books. I doubt if Ennius would have felt that the early Latin war with the story of Lake Regillus, the capture of Veii, the Allia, the fall of Rome to the Gauls, and the second Samnite war (the Caudine forks!) were minor wars; but I am certain that bellum in the singular, except in contrast to the notion of pax, cannot refer to war in a general sense, covering a plurality of wars.

Sign in / Sign up

Export Citation Format

Share Document